UroToday

REVELUTION Trial: A Comparative Study of GnRH Agonist and Antagonist on Coronary Plaque in Prostate Cancer - Sagar Patel

Sagar Patel presents the REVELUTION trial comparing leuprolide versus relugolix effects on coronary plaque progression in 94 men with non-metastatic prostate cancer receiving pelvic radiotherapy.
UroToday

Phase 3 INDICATE Trial for Patients with Biochemically Recurrent Prostate Cancer - Neha Vapiwala

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday

Updates in bladder and prostate pathology: Diagnostic consensus and clinical relevance.

Accurate grading, staging, and classification are essential components of bladder and prostate cancer pathology, directly influencing clinical management and patient outcomes. Recent initiatives by ...
UroToday

Outcomes Reported for Hunner Lesion Resection with Hydrodistension in Interstitial Cystitis - Yoshiyuki Akiyama

Alan Wein: Hello, it's Alan Wein from UroToday. And today we have a special treat for you all the way from Japan, Professor Yoshiyuki Akiyama, who's the professor and chair of the Department of ...
UroToday

Study Investigates an AI-Powered Prognostic Test in Salvage Radiation Therapy Patients - Paul Nguyen

Paul Nguyen discusses the Artera AI prostate test for post-prostatectomy BCR. The test combines clinical factors with AI-analyzed digital pathology from prostatectomy specimens. Validation using RTOG ...
UroToday

Improving Patient Involvement in Care-A Pilot Study of a Comprehensive Pelvic Floor Muscle Exercise Program Before and After Radical Prostatectomy to Prevent Urinary Leakage

Aged ≥18 years with prostate cancer scheduled for radical prostatectomy at MSK ...
UroToday

Comparing Minimally Invasive Surgical Therapies for Benign Prostatic Hyperplasia - Dean Elterman

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday

Treatment of biochemical recurrence after primary therapy with curative intent.

We aimed to summarize the recent advancements in management of biochemical recurrence (BCR) after primary curative therapy for prostate cancer (PCa), and the role of advanced imaging technologies in ...
UroToday

Use of doublet or triplet therapy in metastatic hormone-sensitive prostate cancer across community-based urology settings in the US.

This study examines patient clinical profiles and real-world utilization patterns of darolutamide doublet (+ADT alone) and triplet therapy (+ADT and docetaxel) for the treatment of metastatic ...
UroToday

Current Status of Neoadjuvant Treatment Before Surgery in High-Risk Localized Prostate Cancer - Beyond the Abstract

High-risk localized prostate cancer (HR PCa) presents a significant clinical challenge due to its high risk of recurrence, metastatic progression, and cancer-specific mortality following initial ...
UroToday

FAP and Nectin-4 Targeted Imaging and Therapy in Urothelial Cancer "Presentation" - Vadim Koshkin

At the 2025 UCSF-UCLA PSMA Conference, Vadim Koshkin discusses radioligand therapies for bladder cancer. He highlights that gallium-FAP-2286 imaging shows bladder cancer has the highest FAP uptake ...
UroToday

When Should We Use 18F-FDG PET? "Presentation" - Andrei Iagaru

At the 2025 UCSF-UCLA PSMA Conference, Dr. Iagaru advocates for FDG-PET in advanced prostate cancer, particularly for lutetium PSMA therapy candidates. He challenges the notion that imaging is ...